NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.

The company embarked on a clinical trial of Vyoo, its PCR- and array-based sepsis test, in 2011, and said this week that it completed the trial at the end of last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.